Celyad Oncology S.A.

CLYYF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$5,824-$8,448-$40,935-$26,512
Dep. & Amort.$450$794$1,440$1,520
Deferred Tax$0$0$0-$531
Stock-Based Comp.$0$935$1,624$2,172
Change in WC-$177-$1,205-$4,015$1,405
Other Non-Cash-$129-$7,278$13,876-$4,697
Operating Cash Flow-$5,680-$15,202-$28,010-$26,643
Investing Activities
PP&E Inv.-$118-$934-$123-$393
Net Acquisitions$15$0$6,000$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$1,090$0
Other Inv. Act.$0$1,341$235$267
Investing Cash Flow-$103$407$7,202-$126
Financing Activities
Debt Repay.-$167-$145-$896-$1,136
Stock Issued$0$9,490$0$36,568
Stock Repurch.$0$0-$124$0
Dividends Paid$0$0$0$0
Other Fin. Act.$3,150$10$4,261$4,089
Financing Cash Flow$2,983$9,355$3,241$39,521
Forex Effect-$4-$1-$6$32
Net Chg. in Cash-$2,804-$5,441-$17,573$12,784
Supplemental Information
Beg. Cash$7,004$12,445$30,018$17,234
End Cash$4,200$7,004$12,445$30,018
Free Cash Flow-$5,680-$16,101-$28,133-$27,036